Ka-Ching: F. Michael Ball cashes out of Hospira with $91.1M

Eric Palmer Early indications that CEO F. Michael Ball would cash out with $ 80 million when Pfizer completed its buyout of Hospira were clearly off the mark. Instead ...

UPDATED: AstraZeneca scores FDA nod for long-term Brilinta use

Carly Helfand AstraZeneca's blood thinner Brilinta is officially one step closer to living up to the British pharma's $ 3.5 billion ambitions. The FDA has handed down an approval ...

Genzyme vets raise $37.5M for a new cancer biotech

Damian Garde The stealthy X4 Pharmaceuticals, run by some of former Genzyme execs, has raised $ 37.5 million to fund its work on new cancer treatments. FierceBiotech News

MD Anderson adds Cellectis to a crush of immunotherapy collaborations

John Carroll The MD Anderson Cancer Center in Houston is becoming the preferred partner of choice among a growing group of immuno-oncology players looking to develop a new generation ...

Report: Baxalta’s $2B plot to buy Ariad broke down over price

Damian Garde Last week's buzz that Baxalta, angling to shake off some unwanted buyout attention from Shire, had set sights on Ariad Pharmaceuticals sent the latter company's ...

Stem cell researcher cleared of misconduct after U-turn

Nick Paul Taylor A stem cell researcher who was accused by colleagues of making up data has been cleared of scientific misconduct. The decision is a boost for Dr. Paolo Macchiarini, ...

Allergan recalls eye drugs after patients complain of particles, blurred vision

Carly Helfand Since Allergan and Actavis joined hands to become a new-look Allergan, the company has already had to recall a from the Actavis side. Now, it's recalling one from ...

Raptor buys into cystic fibrosis with a $418M deal

Damian Garde Rare disease biotech Raptor Pharmaceutical signed a deal to pay up to $ 418 million to Tripex Pharmaceuticals in exchange for an inhaled treatment for cystic fibrosis. FierceBiotech ...

Troubled Lundbeck targets 1,000 layoffs in HQ, commercial revamp

Tracy Staton Lundbeck is going on a cost-cutting binge. Amid falling sales–and a few months after a new CEO took the helm–the Danish drugmaker says it will cut loose ...

FDA clears a controversial female libido drug despite ‘modest’ effects and dangerous risks

Damian Garde The FDA cleared Sprout Pharmaceuticals' much-scrutinized flibanserin, a first-of-its-kind pill designed to boost women's sexual desire, but not without sticking ...

CRO giant WuXi is going private in a $3.3B deal

Damian Garde WuXi PharmaTech, China's largest CRO, agreed to a $ 3.3 billion buyout deal that would take it off of Wall Street and into the hands of some private investors. FierceBiotech ...

AbbVie falls short on Q2 sales–but don’t blame biosimilars, CEO says

Carly Helfand Huge sales leaps for AbbVie's Humira have been powering revenue forecast beats for the company in recent quarters. But this time, international sales of ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS